Side effects
Hair loss on Foundayo
The label reports it, and explains it more than most. Hair loss was reported by 4 to 5 percent of people on Foundayo against 2 percent on placebo, and the label ties it to weight reduction rather than to the molecule. It is far more common in women: 7 percent against 0.9 percent of men on Foundayo, and 3 percent against 0.7 percent on placebo.
DM, the one who read the label
Sources checked Oct 7, 2026
Published Oct 23, 2026
Updated Oct 7, 2026 · 1 min read
The short answer
The label reports it, and explains it more than most. Hair loss was reported by 4 to 5 percent of people on Foundayo against 2 percent on placebo, and the label ties it to weight reduction rather than to the molecule. It is far more common in women: 7 percent against 0.9 percent of men on Foundayo, and 3 percent against 0.7 percent on placebo.
What the label says
Hair loss closes the Foundayo side effect table, and then gets a paragraph of its own.
From the labelHair loss adverse reactions in FOUNDAYO-treated patients were associated with weight reduction. In a pool of Trials 1 and 2, hair loss was reported more frequently in female than male patients in the FOUNDAYO (7% female versus 0.9% male) and placebo (3% female versus 0.7% male) treatment groups.
Two things the label rarely does on a side effect line: it names a cause, the weight change, and it gives the split by sex, with placebo alongside.
Reading the placebo numbers
Three percent of women on placebo reported hair loss. They were losing weight too, on the lifestyle programme every trial participant followed. That is the label's evidence for its own sentence: the shedding follows the change, whichever tablet, or no tablet, is behind it.
What people actually do
Hair threads appear on the Foundayo forums a few months in, with the same brush photos as on every other GLP-1 forum. The pattern described is shedding that starts weeks after a stretch of fast change and eases later. What the Foundayo label adds to those threads is the reason and the split, which is more than most people have been told.
The useful thing to bring to the prescriber is the timeline: the strengths, the pace of change, when the shedding started. The label's sentence turns that timeline into a conversation about pace rather than about stopping.
Oolite's journal keeps the timeline by strength, so the conversation starts from dates.
Questions people ask
Does it get worse at higher strengths?
The label's table gives 4 percent at 5.5 and 9 mg and 5 percent at 17.2 mg, against 2 percent on placebo. A small climb.
Why women more than men?
The label reports the split without explaining it: 7 percent of women against 0.9 percent of men on Foundayo, and 3 percent against 0.7 percent on placebo. Women lose hair on placebo more often too, which points at the weight change rather than the tablet.
Does it come back?
The label does not describe the course. It neither says it is permanent nor promises regrowth. A prescriber or a dermatologist can say more.
Should I stop the tablet because of it?
That is a prescriber decision. The label connects the shedding to the weight change, which is a reason to talk about the pace before talking about stopping.
Sources
- Foundayo prescribing information, Eli Lilly, §6.1, Table 1 and the hair loss paragraph, revised 07/2026 · Hair loss 2 percent placebo vs 4, 4 and 5 percent at 5.5, 9 and 17.2 mg; associated with weight reduction; 7 percent of women vs 0.9 percent of men on Foundayo, 3 vs 0.7 percent on placebo.
Sources checked Oct 7, 2026. This page is information, not medical advice: read the medical disclaimer, and talk to your prescriber or pharmacist about your own treatment.
Written by
DM, the one who read the label
I make Oolite. I read every label revision the day it comes out and rewrite these answers when they change.
How these pages are madeOolite
The GLP-1 tracker for the pill and the shot.
The 30 minute timer, your shot day, the level chart and the dose reminder, on iPhone, with Apple Watch to log. Free to download, then a 14-day free trial.
